During a Pandemic, Direct Democracy Comes by Home Delivery

This spring, the founders of the Boulder ballot initiative campaign Bedrooms Are for People wanted to drum up support for a measure that would amend the city charter and relax the rules around household occupancy in the fast-growing Colorado city. Average rents in Boulder jumped 41% between 2011 and 2018, and some YIMBY advocates — those are adherents of the “Yes In My Backyard” movement — targeted a city rule that prevents more […]

» Read more

The average 401(k) balance by age, income level, gender, and industry

Personal Finance Insider writes about products, strategies, and tips to help you make smart decisions with your money. We may receive a small commission from our partners, like American Express, but our reporting and recommendations are always independent and objective. The average 401(k) balance is $92,148, according to a 2019 Vanguard analysis of over 5 million 401(k) plans issued by […]

» Read more

The best men's T-shirts you can buy

The T-shirt has evolved from an unseen undergarment into one of the most popular and prominent articles of clothing. We've tried many different kinds over the years, and narrowed down the tried-and-true options for every category, from undershirts to athletic wear. The Everlane Uniform Cotton Crew is our top pick overall because it's affordable, available in many colors, durable, and […]

» Read more

EQ Soars, INMB Up On Promising Alzheimer’s Trial Data, ALT To Move AdCOVID Into Clinical Trial In Q4

Today’s Daily Dose brings you news about Altimmune’s progress in ints intranasal COVID-19 vaccine candidate, Independent Data Monitoring Committee recommending stopping of Celsion’s phase III OPTIMA study, FDA refusing to accept for review CytoDyn’s Biologics License Application for Leronlimab, multi-fold jump in the share price of Equillium, and promising Alzheimer’s trial data of INmune Bio, among others. Read on… 1. […]

» Read more

Stocks will see ‘significant new highs’ if there is a breakthrough in COVID-19 vaccine development, Fundstrat’s Tom Lee says

Stocks are set to see “significant new highs” if there is a positive breakthrough in the race to develop a successful COVID-19 vaccine, Fundstrat’s Tom Lee said on Monday. In an interview with CNBC’s Scott Wapner, Lee said the chances of a breakthrough look good given that there are 133 vaccines candidates currently in development. “By December I think you’re […]

» Read more

Don’t Hype the Hope for Oxford-AstraZeneca Covid Vaccine

In this article After months of hype, the world finally has human trial data from a front-running vaccine collaboration between the University of Oxford and AstraZeneca Plc. Spoiler alert, it’s good news. The data, published in The Lancet Monday, showed that the vaccine produced an encouraging immune response. Just as crucially, perhaps, no significant safety issues emerged. Investors took these developments as a […]

» Read more

Roku Is A “Strong Gatekeeper” In Streaming, But Could Be Crushed By Big Tech – Analyst

Roku has established its position as a “strong gatekeeper” in streaming, poised to benefit from an influx in advertising, but it is also a small fish swimming in the vast ocean controlled by major tech firms. That’s the mixed signal from MoffettNathanson analysts Michael Nathanson, who initiated coverage of Roku with a “neutral” rating and a 12-month price target of […]

» Read more
1 25 26 27 28 29 90